TGFB1 and neoplasm: Other targeting strategies include targeting ECM to allow drug access to tumor cells, TGF-β1 inhibition to prevent tumor progression by facilitating T cell infiltration, and reprogramming CAFs back to a quiescent state by using vitamin A and D agonists to increase the efficacy of chemotherapy (Sherman et al., 2014; Shany et al., 2016; Liu et al., 2019b).